Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID
Links shared publicly online about this topic.
- 821total visits
Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
View full resource at news-medical.net
Tags: Immune, Immune Deficiency, Pelvic Inflammatory Disease
Most Recently Shared on October 6, 2010 at 4:34 pm By:
Oncology News: Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID:... http://bit.ly/b43kcS
Also Shared By:
Advertisement
News-Medical.Net
@NewsMedical
Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID: Data from inte... http://bit.ly/b43kcS
1 year ago...